


15m 1626



U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

**SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT**

Docket Number:
1662/50302

Application Number
09/714,351

Filing Date
November 16, 2000

Examiner
Laura Stockton

Art Unit
1626

Invention Title
POLYMORPHIC FORM OF ATORVASTATIN CALCIUM

Inventor(s)
AYALON et al.

Address to:
Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

Date: May 11, 2005
Signature: Kathy Felf

1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 37 C.F.R. § 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicants hereby bring the attached references to the attention of the Examiner. These references are listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom. The filing of this Information Disclosure Statement and the enclosed PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b).
2. Copies of patents, publications or other information listed on the modified PTO Form 1449 are enclosed, unless indicated otherwise.
3. A copy of a Supplemental European Search Report recently received in a corresponding EP application is also enclosed.
4. Applicants' attorney certifies that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.
5. A duplicate copy of this communication is enclosed for charging purposes.

Dated: MAY 10, 2005

By: Joseph A. Coppola
Joseph A. Coppola (Reg. No. 38,413)

CUSTOMER NUMBER 26646

KENYON & KENYON
One Broadway
New York, New York 10004
(212) 425-7200 (telephone)
(212) 425-5288 (facsimile)



MAY 13 2005

**SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT BY
APPLICANT
PTO-1449**ATTY. DOCKET NO.
1662/50302SERIAL NO.
09/714,351APPLICANT
AYALON et al.FILING DATE
November 16, 2000GROUP
1626**U. S. PATENT DOCUMENTS**

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE*

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 97/03958	February 6, 1997	PCT			x	
	WO 97/03959	February 6, 1997	PCT			x	
	WO 01/36384	May 25, 2001	PCT			x	
	WO 01/44180	June 21, 2001	PCT			x	
	WO 01/44181	June 21, 2001	PCT			x	
	WO 02/41834	May 30, 2002	PCT			x	
	WO 02/43732	June 6, 2002	PCT			x	
	WO 02/051804	July 4, 2002	PCT			x	
	WO 02/057229	July 25, 2002	PCT			x	
	WO 03/004470	January 16, 2003	PCT			x	
	WO 03/011826	February 13, 2003	PCT			x	
	WO 03/050085	June 19, 2003	PCT			x	
	WO 2004/022053	March 18, 2004	PCT			x	
	WO 2004/050618	June 17, 2004	PCT			x	

OTHER DOCUMENTS

EXAMINER INITIAL	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

PARTNERS
 ADAM PILCH *
 PENELOPE NICHOLLS †
 NIGEL ROBINSON *
 IAN HARRIS *
 CHARLES HARDING *
 JEREMY PENNANT †
 JAMES TURNER *
 CATHERINE MALLALIEU *
 RICHARD PRATT *
 ANTONIO MASCHIO *
 DAVID HORNER *
 NEIL NACHSHEN * ‡
 MILES HAINES *
 JONATHAN DEVILE *
 DAVID ALCOCK *
 CHONG YEE KHOO *
 LOUISE HOLLIDAY *
 SIMON DAVIES *
 GILLIAN DEAS †
 KIRK GALLAGHER *
 ZOE CLYDE - WATSON *
 AYLISA WILLIAMS *

ASSOCIATES
 PAUL PRICE *
 JILL MATCHETT †
 JAMES TANNER *
 JULIA MILLS *
 ANGELA THORNTON - JACKSON †
 CATHERINE MCGOWAN *
 ISLA FURLONG *
 WILLIAM ILLINGWORTH - LAW *
 JOSEPHINE BRADLEY *
 KARA BEARFIELD †
 DAVID MELDRUM *
 GARETH FENNELL *
 CANDIDA SOAMES *
 ANDREW LEPPARD *
 KIT WONG *
 ADRIAN BRADLEY *

CONSULTANTS
 IVAN COTTER *
 DAVID CRISP *
 JOHN ARDLEY, OBE §
 JANE HARLOW †

ADMINISTRATION
 KEITH TESTER (DIRECTOR OF OPERATIONS)
 DAVID SHARPE (PATENT AND DESIGN RECORDS
 AND RENEWALS)
 SHARON SEQUEIRA (TRADE MARK RECORDS
 AND RENEWALS)

* CHARTERED PATENT ATTORNEY AND EUROPEAN
 PATENT ATTORNEY
 † EUROPEAN TRADE MARK ATTORNEY
 § CONSULTANT IN PLANT BREEDERS' RIGHTS ONLY
 ‡ PATENT AGENT LITIGATOR

D. YOUNG & CO

CHARTERED PATENT ATTORNEYS
 EUROPEAN PATENT ATTORNEYS
 EUROPEAN TRADE MARK ATTORNEYS
 EUROPEAN DESIGN ATTORNEYS

120 HOLBORN
 LONDON
 EC1N 2DY

TELEPHONE: +44 (0) 20 7269 8550


FAX: +44 (0) 20 7269 8555

E MAIL: mail@dyoung.co.uk

WEBSITE: www.dyoung.com

DX.0078 LONDON, CHANCERY LANE

ALSO AT MUNICH



COPY

KATHY FALL
 Ms Galit Gonen-Cohen,
 Teva Pharmaceutical Industries Ltd.,
 Patents Department,
 5 Basel Street,
 P.O. Box 3190,
 Petah Tiqva 49131,
 Israel.

Our Ref: P020440EP JNB CHM
 Your Ref: 3977-A-PCT-EP

CC: Patrick J. Birde, Kenyon & Kenyon (Ref: 1662/503364)
 Lori Azuolay, Teva Pharmaceutical Industries Ltd.

27 April 2005

Dear Galit,

European Patent Application No. 03713610.8

Regional Phase of PCT/US03/05384

"Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation, as well as novel processes for preparing atorvastatin hemi-calcium forms I, VIII and IX"

Teva Pharmaceutical Industries Ltd.

I enclose a copy of an Official Letter from the EPO dated 6 April 2005 which includes a copy of the EPO Supplementary Search Report, a copy of a list of equivalents provided by the EPO and copies of the cited references. As you will see, the Search Examiner considers eleven of the cited references to be particularly relevant if taken alone but the Substantive Examiner in Munich may take a different view.

There is no need to comment on the references or file amendments at this stage but if we do so, this may expedite prosecution.

We will shortly receive an Official Letter setting a term of two months within which time we must confirm to the European Patent Office that the application is to proceed to full examination.

DOCKET DEPARTMENT

DOCKETED BY _____

CHECKED BY ALB 5/5/05

27 April 2005

- 2 -

D. YOUNG & CO.

I will contact you again when I receive the expected Official Letter. In the meantime, I enclose our debit note.

Yours sincerely,
for D Young & Co

Jo Bradley